September 19, 2019Open Access

Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years

Key Points

Key points are not available for this paper at this time.

Abstract

Key Points Patients with t-MDS are underrepresented in clinical trials when taking into account the prevalence of such patients. Eligibility criteria and sponsorship type may contribute to t-MDS patient exclusion.

KI fragen

Bookmark

View Full Paper

Cite This Study

Borate et al. (Thu,) studied this question.

synapsesocial.com/papers/69dcbd110de68e8319e533e1 https://doi.org/https://doi.org/10.1182/bloodadvances.2019000293

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response2011 · 30 citations
2Eligibility Criteria of Randomized Controlled Trials2007 · 6 citations
3Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT32010 · 503 citations
4Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes2006 · 106 citations
5Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome2010 · 134 citations

KI fragen

Bookmark

View Full Paper